TTR and cutaneous mastocytosis: Contemporary data from a large referral center in the post-tafamidis period suggests that NAC staging is still highly prognostic in patients on transthyretin stabilizers; however, a large proportion of patients are still significantly advanced in their disease presentation, with 56% of patients with ATTR-CM being diagnosed with NAC stage II or III disease (Figure 3).45 Despite a rapid increase in the volume of cardiac scintigraphy performed at amyloidosis centers, the median time from symptom onset to diagnosis of ATTRwt-CM has not changed in large registry studies.36,46,47